is there a use for anti-pdl-1 antibodies in recurrent head and neck cancer?
Published 6 years ago • 164 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
3:13
pd-l1 and alternative biomarkers in head and neck cancer
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
2:19
elucidating novel biomarkers for head and neck cancers
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
1:57
targeting pd-1 and pd-l1 for lung cancer therapy
-
3:50
the role of pd-l1: is it accurate enough as a biomarker for immunotherapy response?
-
2:13
the value of pd-l1 as a biomarker beyond lung cancers
-
3:15
phase ii study of petosemtamab and pembrolizumab for recurrent/metastatic hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
1:40
anti-pd-l1/tgf-β trap in non-hpv associated hnscc
-
2:14
innovative approaches to the treatment of head and neck cancer
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
2:35
an update of knowledge for pd-l1 in head and neck cancers
-
7:09
personalizing immunotherapy beyond pdl1 expression
-
0:54
the role of immunotherapy in pd-l1 low advanced squamous cell carcinoma
-
2:38
exciting results of the scores trial
-
3:08
improved survival, toxicity & qol with pembrolizumab in head and neck cancer
-
5:02
going beyond pd-l1 testing for lung cancer immunotherapy